Novo Nordisk strikes second licensing deal since frosty capital-markets day
Single source Only one publisher in our feeds has reported this so far. Treat details as unconfirmed.
ملخص الناشر — MarketWatch
Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.
اقرأ الخبر كاملاً على marketwatch.com
Ledgerline did not write this story. The headline and excerpt come from MarketWatch’s public feed; the full article is on the publisher’s site.